Lee Eaum Seok, Kim Seok Hyun, Kim Hyun Jin, Kim Kyung Hee, Lee Byung Seok, Ku Bon Jeong
Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
Department of Pathology, Chungnam National University School of Medicine, Daejeon, Korea.
Gut Liver. 2017 Mar 15;11(2):276-282. doi: 10.5009/gnl16049.
BACKGROUND/AIMS: Growth differentiation factor 15 (GDF-15) belongs to the transforming growth factor-β superfamily. GDF-15 is emerging as a biomarker for several diseases. The aim of this study was to determine the clinical performances of GDF-15 for the prediction of liver fibrosis and severity in chronic liver disease.
The serum GDF-15 levels were examined via enzyme immunoassay in 145 patients with chronic liver disease and 101 healthy individuals. The patients with chronic liver disease consisted of 54 patients with chronic hepatitis, 44 patients with compensated liver cirrhosis, and 47 patients with decompensated liver cirrhosis.
Of the patients with chronic liver diseases, the decompensated liver cirrhosis patients had an increased serum GDF-15 (3,483 ng/L) level compared with the patients with compensated liver cirrhosis (1,861 ng/L) and chronic hepatitis (1,232 ng/L). The overall diagnostic accuracies of GDF-15, as determined by the area under the receiver operating characteristic curves, were as follows: chronic hepatitis=0.656 (>574 ng/L, sensitivity, 53.7%; specificity, 79.2%), compensated liver cirrhosis=0.886 (>760 ng/L, sensitivity, 75.6%; specificity, 92.1%), and decompensated liver cirrhosis=0.984 (>869 ng/L, sensitivity, 97.9%; specificity, 94.1%).
This investigation represents the first study to demonstrate the availability of GDF-15 in chronic liver disease. GDF-15 comprised a useful biomarker for the prediction of liver fibrosis and severity in chronic liver disease.
背景/目的：生长分化因子15（GDF - 15）属于转化生长因子-β超家族。GDF - 15正成为多种疾病的生物标志物。本研究旨在确定GDF - 15在预测慢性肝病肝纤维化及严重程度方面的临床性能。
采用酶免疫分析法检测145例慢性肝病患者和101例健康个体的血清GDF - 15水平。慢性肝病患者包括54例慢性肝炎患者、44例代偿期肝硬化患者和47例失代偿期肝硬化患者。
在慢性肝病患者中，失代偿期肝硬化患者的血清GDF - 15水平（3483 ng/L）高于代偿期肝硬化患者（1861 ng/L）和慢性肝炎患者（1232 ng/L）。根据受试者工作特征曲线下面积确定的GDF - 15总体诊断准确性如下：慢性肝炎=0.656（>574 ng/L，敏感性53.7%；特异性79.2%），代偿期肝硬化=0.886（>760 ng/L，敏感性75.6%；特异性92.1%），失代偿期肝硬化=0.984（>869 ng/L，敏感性97.9%；特异性94.1%）。
本研究首次证明了GDF - 15在慢性肝病中的可用性。GDF - 15是预测慢性肝病肝纤维化及严重程度的有用生物标志物。
